Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.51 |
| ▸ | NT5E | P21589 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2985322 | 0.86 | P2RY6 (0.51) | P2RY6P2RY14NT5EALDH1A1HTT | |
| SCHEMBL2985316 | 0.86 | P2RY6 (0.51) | P2RY6P2RY14NT5EALDH1A1HTT | |
| SCHEMBL7042565 | 0.85 | P2RY6 (0.52) | P2RY6P2RY14NT5EALDH1A1HTT | |
| SCHEMBL3287903 | 0.83 | P2RY6 (0.43) | P2RY6P2RY14NT5EALDH1A1HTT | |
| SCHEMBL14363434 | 0.83 | P2RY6 (0.43) | P2RY6P2RY14NT5EALDH1A1HTT | |
| SCHEMBL19407978 | 0.83 | P2RY6 (0.43) | P2RY6P2RY14NT5EALDH1A1HTT | |
| SCHEMBL19399414 | 0.83 | P2RY6 (0.43) | P2RY6P2RY14NT5EALDH1A1HTT | |
| SCHEMBL16940272 | 0.83 | P2RY6 (0.43) | P2RY6P2RY14NT5EALDH1A1HTT | |
| SCHEMBL3070618 | 0.83 | TYMP (0.54) | P2RY6P2RY14NT5EALDH1A1HTT | |
| SCHEMBL3070612 | 0.83 | TYMP (0.54) | P2RY6P2RY14NT5EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1629084-A2 | MODULATION OF C-REACTIVE PROTEIN EXPRESSION | Isis Pharmaceuticals, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| EP-1506216-A2 | ANTISENSE MOODULATION OF KINESIN-LIKE 1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2005005599-A2 | MODULATION OF C-REACTIVE PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-6825337-B2 | COMPRISES OLIGONUCLEOTIDES FOR CONTROLLING PHOSPHOLEMMAN-LIKE PROTEIN (PLML) GENE EXPRESSION; ANTICARCINOGENIC AGENTS; TUMOR DIAGNOSIS | ISIS PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| WO-2004015126-A2 | ANTISENSE MODULATION OF EDG1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040002150-A1 | Antisense modulation of hypothetical protein LOC51249 expression | ISIS PHARMACEUTICALS INC. | 2004-01-01 | — | — | US | disclosed |
| WO-2003106645-A2 | ANTISENSE MODULATION OF SMRT EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003102008-A1 | ANTISENSE MODULATION OF TRANSCRIPTION FACTOR DP-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003099224-A2 | ANTISENSE MOODULATION OF KINESIN-LIKE 1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030225014-A1 | Antisense modulation of PLML expression | ISIS PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003088921-A2 | ANTISENSE MODULATION OF HYDROXYSTEROID 11-BETA DEHYDROGENASE 1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |